AstraZeneca's Imfinzi combined with chemotherapy in TOPAZ-1 trial showed a 26% risk reduction in death for advanced biliary tract cancer patients.

AstraZeneca's Imfinzi (durvalumab) combined with chemotherapy in the TOPAZ-1 Phase 3 trial showed a 26% risk reduction in death for advanced biliary tract cancer patients, with a median overall survival of 12.9 months for the Imfinzi combo vs. 11.3 months for chemotherapy alone. Twice as many patients were alive at three years in the Imfinzi group.